Onlystar Biotechnology

Onlystar Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the development of targeted protein degradation (TPD) therapies. The company utilizes its proprietary PROTAC platform to design small molecules that facilitate the degradation of disease-causing proteins by the ubiquitin-proteasome system. Its lead candidate, OLS-001, is an orally bioavailable Androgen Receptor degrader currently in Phase 1 clinical trials for the treatment of metastatic castration-resistant prostate cancer. Onlystar's pipeline also includes programs targeting other high-value oncology and immunology markers, such as BTK and ER, aiming to provide new treatment options for patients with resistant or refractory diseases.